, Volume 26, Issue 3, pp 667–674 | Cite as

Oxidative stress as a possible mechanism of statin-induced myopathy

  • Yasin Ahmadi
  • Amir Ghorbanihaghjo
  • Mohsen Naghi-Zadeh
  • Neda Lotfi Yagin


Statins, inhibitors of hydroxy methyl glutaryl coenzyme-A (HMG-CoA) reductase, are the most widely used drugs for treating hypercholesterolemia. However, statins can cause disabling myopathy as their main adverse effect. Several molecular mechanisms underlie the statin-induced myopathy including the decrease in the levels of essential mevalonate and cholesterol derivatives. This review discusses a further mechanism involving the loss of other anti-oxidant defenses besides ubiquinone (Co-Q) in skeletal muscles which produce a significant amount of reactive oxygen species (ROS). Therefore, to maintain their function, skeletal muscles need a high level of anti-oxidants.


Cholesterol Myopathy Oxidative stress Statins Ubiquinone 


Compliance with ethical standards

Conflict of interest

All authors declare that they have no conflict of interest.


  1. Ahmadi Y, Ghorbanihaghjo A, Argani H (2017) The balance between induction and inhibition of mevalonate pathway regulates cancer suppression by statins: a review of molecular mechanisms. Chemico Biol Interact 273:273–285CrossRefGoogle Scholar
  2. Ames BN (1989) Endogenous oxidative DNA damage, aging, and cancer. Free Radic Res Commun 7:121–128PubMedCrossRefGoogle Scholar
  3. Anto RJ, Kuttan G, Babu K, Rajasekharan K, Kuttan R (1998) Anti-inflammatory activity of natural and synthetic curcuminoids. Pharm Pharmacol Commun 4:103–106Google Scholar
  4. Barja G (1999) Mitochondrial oxygen radical generation and leak: sites of production in states 4 and 3, organ specificity, and relation to aging and longevity. J Bioenergy Biomembr 31:347–366CrossRefGoogle Scholar
  5. Basraon SK, Menon R, Makhlouf M, Longo M, Hankins GD, Saade GR, Costantine MM (2012) Can statins reduce the inflammatory response associated with preterm birth in an animal model? Am J Obstet Gynecol 207:224.e221–224.e227CrossRefGoogle Scholar
  6. Bełtowski J (2008) Liver X receptors (LXR) as therapeutic targets in dyslipidemia. Cardiovasc Ther 26:297–316PubMedCrossRefGoogle Scholar
  7. Bloor W (1936) The cholesterol content of muscle. J Biol Chem 114:639–648Google Scholar
  8. Bonetti P, Lerman LO, Napoli C, Lerman A (2003) Statin effects beyond lipid lowering—are they clinically relevant? Eur Heart J 24:225–248PubMedCrossRefGoogle Scholar
  9. Brand MD (2010) The sites and topology of mitochondrial superoxide production. Exp Gerontol 45:466–472PubMedPubMedCentralCrossRefGoogle Scholar
  10. Brown AJ (2007) Cholesterol, statins and cancer. Clin Exp Pharmacol Physiol 34:135–141PubMedCrossRefGoogle Scholar
  11. Cabreiro F, Picot CR, Friguet B, Petropoulos I (2006) Methionine sulfoxide reductases. Ann N Y Acad Sci 1067:37–44PubMedCrossRefGoogle Scholar
  12. Cadenas E, Davies KJ (2000) Mitochondrial free radical generation, oxidative stress, and aging. Free Radic Biol Med 29:222–230PubMedCrossRefGoogle Scholar
  13. Cafforio P, Dammacco F, Gernone A, Silvestris F (2005) Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis 26:883–891PubMedCrossRefGoogle Scholar
  14. Caso G, Kelly P, McNurlan MA, Lawson WE (2007) Effect of coenzyme q10 on myopathic symptoms in patients treated with statins. Am J Cardiol 99:1409–1412PubMedCrossRefGoogle Scholar
  15. Cauley JA et al (2006) Statin use and breast cancer: prospective results from the Women’s Health Initiative. J Natl Cancer Inst 98:700–707PubMedCrossRefGoogle Scholar
  16. Cerda A, Hirata MH, Hirata RDC (2012) Molecular mechanisms underlying statin effects on genes involved in the reverse cholesterol transport. Drug Metab Personal Ther 27:101–111Google Scholar
  17. Cooke MS, Evans MD, Dizdaroglu M, Lunec J (2003) Oxidative DNA damage: mechanisms, mutation, and disease. FASEB J 17:1195–1214PubMedCrossRefGoogle Scholar
  18. Cuchel M, Rader DJ (2006) Macrophage reverse cholesterol transport key to the regression of atherosclerosis? Circulation 113:2548–2555PubMedCrossRefGoogle Scholar
  19. Das U (1999) Essential fatty acids, lipid peroxidation and apoptosis. Prostaglandins Leukotrienes Essent Fatty Acids (PLEFA) 61:157–163CrossRefGoogle Scholar
  20. De Pinieux G et al (1996) Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Br J Clin Pharmacol 42:333–337PubMedCrossRefGoogle Scholar
  21. Dietschy JM, Gamel WG (1971) Cholesterol synthesis in the intestine of man: regional differences and control mechanisms. J Clin Investig 50:872PubMedPubMedCentralCrossRefGoogle Scholar
  22. Dietschy JM, Siperstein MD (1967) Effect of cholesterol feeding and fasting on sterol synthesis in seventeen tissues of the rat. J Lipid Res 8:97–104PubMedGoogle Scholar
  23. Dietschy JM, Wilson JD (1968) Cholesterol synthesis in the squirrel monkey: relative rates of synthesis in various tissues and mechanisms of control. J Clin Investig 47:166PubMedPubMedCentralCrossRefGoogle Scholar
  24. Dirks AJ, Jones KM (2006) Statin-induced apoptosis and skeletal myopathy. Am J Physiol Cell Physiol 291:C1208–C1212PubMedCrossRefGoogle Scholar
  25. Dulak J et al (2005) Atorvastatin affects several angiogenic mediators in human endothelial cells. Endothelium 12:233–241PubMedPubMedCentralCrossRefGoogle Scholar
  26. Duncan RE, El-Sohemy A, Archer MC (2005) Statins and cancer development. Cancer Epidemiol Biomark Prev 14:1897–1898CrossRefGoogle Scholar
  27. Erdös B, Snipes JA, Tulbert CD, Katakam P, Miller AW, Busija DW (2006) Rosuvastatin improves cerebrovascular function in Zucker obese rats by inhibiting NAD (P) H oxidase-dependent superoxide production. Am J Physiol Heart Circ Physiol 290:H1264–H1270PubMedCrossRefGoogle Scholar
  28. Etienne-Manneville S, Hall A (2002) Rho GTPases in cell biology. Nature 420:629–635PubMedCrossRefGoogle Scholar
  29. Farmer JA (2013) The effect of statins on skeletal muscle function: the STOMP trial. Curr Atheroscler Rep 15:1–3CrossRefGoogle Scholar
  30. Farwell WR, Scranton RE, Lawler EV, Lew RA, Brophy MT, Fiore LD, Gaziano JM (2008) The association between statins and cancer incidence in a veterans population. J Natl Cancer Inst 100:134–139PubMedCrossRefGoogle Scholar
  31. Fernandez G, Spatz ES, Jablecki C, Phillips PS (2011) Statin myopathy: a common dilemma not reflected in clinical trials. Clevel Clin J Med 78:393CrossRefGoogle Scholar
  32. Finkel T, Holbrook NJ (2000) Oxidants, oxidative stress and the biology of ageing. Nature 408:239–247PubMedCrossRefGoogle Scholar
  33. Germershausen JI, Hunt VM, Bostedor RG, Bailey PJ, Karkas JD, Alberts AW (1989) Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo. Biochem Biophys Res Commun 158:667–675PubMedCrossRefGoogle Scholar
  34. Guijarro C et al (1998) 3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res 83:490–500PubMedCrossRefGoogle Scholar
  35. Guijarro C, Blanco-Colio LM, Massy ZA, O’Donnell MP, Kasiske BL, Keane WF, Egido J (1999) Lipophilic statins induce apoptosis of human vascular smooth muscle cells. Kidney Int 56:S88–S91CrossRefGoogle Scholar
  36. Hot A, Lavocat F, Lenief V, Miossec P (2012) Simvastatin inhibits the pro-inflammatory and pro-thrombotic effects of IL-17 and TNF-α on endothelial cells. Ann Rheumatic Dis. CrossRefGoogle Scholar
  37. Hu J, Zhang Z, Shen W-J, Azhar S (2010) Cellular cholesterol delivery, intracellular processing and utilization for biosynthesis of steroid hormones. Nutr Metab 7:47CrossRefGoogle Scholar
  38. Igel M, Sudhop T, Bergmann K (2002) Pharmacology of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), including rosuvastatin and pitavastatin. J Clin Pharmacol 42:835–845PubMedCrossRefGoogle Scholar
  39. Inoue I et al (2000) Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of mRNA levels for interleukin-1β, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor α (PPARα) in primary endothelial cells. Life Sci 67:863–876PubMedCrossRefGoogle Scholar
  40. Jadhav S, Nimbalkar S, Kulkarni A, Madhavi D (1995) Lipid oxidation in biological and food systems. Food science and technology. Marcel Dekker, New York. pp 5–64Google Scholar
  41. Jaffe AB, Hall A (2005) Rho GTPases: biochemistry and biology. Annu Rev Cell Dev Biol 21:247–269PubMedCrossRefGoogle Scholar
  42. Jain MK, Ridker PM (2005) Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov 4:977–987PubMedCrossRefGoogle Scholar
  43. Jasiñska M, Owczarek J, Orszulak-Michalak D (2007) Statins: a new insight into their mechanisms of action and consequent pleiotropic effects. Pharmacol Rep 59:483PubMedGoogle Scholar
  44. Jeske DJ, Dietschy JM (1980) Regulation of rates of cholesterol synthesis in vivo in the liver and carcass of the rat measured using [3H] water. J Lipid Res 21:364–376PubMedGoogle Scholar
  45. Johnson TE, Zhang X, Bleicher KB, Dysart G, Loughlin AF, Schaefer WH, Umbenhauer DR (2004) Statins induce apoptosis in rat and human myotube cultures by inhibiting protein geranylgeranylation but not ubiquinone. Toxicol Appl Pharmacol 200:237–250PubMedCrossRefGoogle Scholar
  46. Kagan V, Serbinova E, Packer L (1990) Antioxidant effects of ubiquinones in microsomes and mitochondria are mediated by tocopherol recycling. Biochem Biophys Res Commun 169:851–857PubMedCrossRefGoogle Scholar
  47. Kalra S (2009) The role of Coenzyme Q10 in statin-associated myopathy. Electron Physician 1:2–8Google Scholar
  48. Kamikawa T, Kobayashi A, Yamashita T, Hayashi H, Yamazaki N (1985) Effects of coenzyme Q10 on exercise tolerance in chronic stable angina pectoris. Am J Cardiol 56:247–251PubMedCrossRefGoogle Scholar
  49. Karp I, Behlouli H, LeLorier J, Pilote L (2008) Statins and cancer risk. Am J Med 121:302–309PubMedCrossRefGoogle Scholar
  50. Kaufmann P, Török M, Zahno A, Waldhauser K, Brecht K, Krähenbühl S (2006a) Toxicity of statins on rat skeletal muscle mitochondria. Cell Mol Life Sci 63:2415–2425PubMedCrossRefGoogle Scholar
  51. Kaufmann P, Török M, Zahno A, Waldhauser K, Brecht K, Krähenbühl S (2006b) Toxicity of statins on rat skeletal muscle mitochondria. Cell Mol Life Sci CMLS 63:2415–2425PubMedCrossRefGoogle Scholar
  52. Kim MC et al (2011) Comparison of clinical outcomes of hydrophilic and lipophilic statins in patients with acute myocardial infarction. Korean J Intern Med 26:294PubMedPubMedCentralCrossRefGoogle Scholar
  53. Kuroda J, Ago T, Matsushima S, Zhai P, Schneider MD, Sadoshima J (2010) NADPH oxidase 4 (Nox4) is a major source of oxidative stress in the failing heart. Proc Natl Acad Sci 107:15565–15570PubMedPubMedCentralCrossRefGoogle Scholar
  54. Laaksonen R, Ojala J-P, Tikkanen MJ, Himberg J-J (1994) Serum ubiquinone concentrations after short-and long-term treatment with HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 46:313–317PubMedCrossRefGoogle Scholar
  55. Laaksonen R, Jokelainen K, Sahi T, Tikkanen MJ, Himberg JJ (1995) Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans. Clin Pharmacol Ther 57:62–66PubMedCrossRefGoogle Scholar
  56. Laaksonen R, Jokelainen K, Laakso J, Sahi T, Härkönen M, Tikkanen MJ, Himberg J-J (1996) The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. Am J Cardiol 77:851–854PubMedCrossRefGoogle Scholar
  57. Laaksonen R et al (2006) A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle. PLoS One 1:e97PubMedPubMedCentralCrossRefGoogle Scholar
  58. Lamperti C et al (2005) Muscle coenzyme Q10 level in statin-related myopathy. Arch Neurol 62:1709–1712PubMedCrossRefGoogle Scholar
  59. Lenaz G (2001) The mitochondrial production of reactive oxygen species: mechanisms and implications in human pathology. IUBMB Life 52:159–164PubMedCrossRefGoogle Scholar
  60. Leonarduzzi G, Sottero B, Poli G (2002) Oxidized products of cholesterol: dietary and metabolic origin, and proatherosclerotic effects (review). J Nutr Biochem 13:700–710PubMedCrossRefGoogle Scholar
  61. Littarru GP, Langsjoen P (2007) Coenzyme Q10 and statins: biochemical and clinical implications. Mitochondrion 7:S168–S174PubMedCrossRefGoogle Scholar
  62. Littarru GP, Tiano L (2007) Bioenergetic and antioxidant properties of coenzyme Q10: recent developments. Mol Biotechnol 37:31–37PubMedCrossRefGoogle Scholar
  63. Littarru GP, Tiano L (2010) Clinical aspects of coenzyme Q 10: an update. Nutrition 26:250–254PubMedCrossRefGoogle Scholar
  64. Löw P, Andersson M, Edlund C, Dallner G (1992) Effects of mevinolin treatment on tissue dolichol and ubiquinone levels in the rat. Biochim Biophys Acta (BBA) Lipids Lipid Metab 1165:102–109CrossRefGoogle Scholar
  65. Lowther WT, Weissbach H, Etienne F, Brot N, Matthews BW (2002) The mirrored methionine sulfoxide reductases of Neisseria gonorrhoeae pilB. Nat Struct Mol Biol 9:348Google Scholar
  66. Marcoff L, Thompson PD (2007) The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol 49:2231–2237PubMedCrossRefGoogle Scholar
  67. Maron DJ, Fazio S, Linton MF (2000) Current perspectives on statins. Circulation 101:207–213PubMedCrossRefGoogle Scholar
  68. McTaggart F (2003) Comparative pharmacology of rosuvastatin. Atheroscler Suppl 4:9–14PubMedCrossRefGoogle Scholar
  69. Menon VP, Sudheer AR (2007) Antioxidant and anti-inflammatory properties of curcumin. In: Aggarwal BB, Surh Y-J, Shishodia S (eds) The molecular targets and therapeutic uses of curcumin in health and disease. Springer, Berlin. pp 105–125CrossRefGoogle Scholar
  70. Mortensen S, Leth A, Agner E, Rohde M (1997) Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Mol Asp Med 18:137–144CrossRefGoogle Scholar
  71. Nam N-H (2006) Naturally occurring NF-κB inhibitors. Mini Rev Med Chem 6:945–951PubMedCrossRefGoogle Scholar
  72. Nelson KK, Melendez JA (2004) Serial review: the powerhouse takes control of the cell: the role of mitochondria in signal transduction. Free Radic Biol Med 37:768–784PubMedCrossRefGoogle Scholar
  73. Ortego M, Bustos C, Hernández-Presa MA, Tuñón J, Dı́az C, Hernández G, Egido J (1999) Atorvastatin reduces NF-κB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis 147:253–261PubMedCrossRefGoogle Scholar
  74. Owczarek J, Jasiñska M, Orszulak-Michalak D (2005) Drug-induced myopathies. An overview of the possible mechanisms. Pharmacol Rep 57:23–34PubMedGoogle Scholar
  75. Ozbek E, Cekmen M, Ilbey YO, Simsek A, Polat EC, Somay A (2009) Atorvastatin prevents gentamicin-induced renal damage in rats through the inhibition of p38-MAPK and NF-kB pathways. Ren Fail 31:382–392PubMedCrossRefGoogle Scholar
  76. Päivä H et al (2005) High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial. Clin Pharmacol Ther 78:60–68PubMedCrossRefGoogle Scholar
  77. Panahi Y, Rahimnia AR, Sharafi M, Alishiri G, Saburi A, Sahebkar A (2014) Curcuminoid treatment for knee osteoarthritis: a randomized double-blind placebo-controlled trial. Phytother Res 28:1625–1631PubMedCrossRefGoogle Scholar
  78. Panahi Y, Ahmadi Y, Teymouri M, Johnston TP, Sahebkar A (2016) Curcumin as a potential candidate for treating hyperlipidemia: a review of cellular and metabolic mechanisms. J Cell Physiol 233:141–152CrossRefGoogle Scholar
  79. Park S-Y et al (2014) Cardiac, skeletal, and smooth muscle mitochondrial respiration: are all mitochondria created equal? Am J Physiol Heart Circ Physiol 307:H346–H352PubMedPubMedCentralCrossRefGoogle Scholar
  80. Perona R, Montaner S, Saniger L, Sanchez-Perez I, Bravo R, Lacal JC (1997) Activation of the nuclear factor-kappaB by Rho, CDC42, and Rac-1 proteins. Genes Dev 11:463–475PubMedCrossRefGoogle Scholar
  81. Porter C, Wall BT (2012) Skeletal muscle mitochondrial function: is it quality or quantity that makes the difference in insulin resistance? J Physiol 590:5935–5936PubMedPubMedCentralCrossRefGoogle Scholar
  82. Poston L, Raijmakers M (2004) Trophoblast oxidative stress, antioxidants and pregnancy outcome—a review. Placenta 25:S72–S78PubMedCrossRefGoogle Scholar
  83. Raha S, Robinson BH (2000) Mitochondria, oxygen free radicals, disease and ageing. Trends Biochem Sci 25:502–508PubMedCrossRefGoogle Scholar
  84. Riley P (1994) Free radicals in biology: oxidative stress and the effects of ionizing radiation. Int J Radiat Biol 65:27–33PubMedCrossRefGoogle Scholar
  85. Rosenson RS (2004) Current overview of statin-induced myopathy. Am J Med 116:408–416PubMedCrossRefGoogle Scholar
  86. Sakamoto T et al (2007) Usefulness of hydrophilic vs lipophilic statins after acute myocardial infarction. Circ J 71:1348–1353PubMedCrossRefGoogle Scholar
  87. Sánchez-Valle V, Chavez-Tapia NC, Uribe M, Méndez-Sánchez N (2012) Role of oxidative stress and molecular changes in liver fibrosis: a review. Curr Med Chem 19:4850–4860PubMedCrossRefGoogle Scholar
  88. Satoh K, Yamato A, Nakai T, Hoshi K, Ichihara K (1995) Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on mitochondrial respiration in ischaemic dog hearts. Br J Pharmacol 116:1894–1898PubMedPubMedCentralCrossRefGoogle Scholar
  89. Schaars CF, Stalenhoef AF (2008) Effects of ubiquinone (coenzyme Q10) on myopathy in statin users. Curr Opin Lipidol 19:553–557PubMedCrossRefGoogle Scholar
  90. Schirris TJ et al (2015) Statin-induced myopathy is associated with mitochondrial complex III inhibition. Cell Metab 22:399–407PubMedCrossRefGoogle Scholar
  91. Shin SK, Ha TY, McGregor RA, Choi MS (2011) Long-term curcumin administration protects against atherosclerosis via hepatic regulation of lipoprotein cholesterol metabolism. Mol Nutr Food Res 55:1829–1840PubMedCrossRefGoogle Scholar
  92. Shrivastava S, Pucadyil TJ, Paila YD, Ganguly S, Chattopadhyay A (2010) Chronic cholesterol depletion using statin impairs the function and dynamics of human serotonin1A receptors. Biochemistry 49:5426–5435PubMedCrossRefGoogle Scholar
  93. Sies H (1997) Oxidative stress: oxidants and antioxidants. Exp Physiol 82:291–295PubMedCrossRefGoogle Scholar
  94. Sinzinger H (2000) Does vitamin E beneficially affect muscle pains during HMG-Co-enzyme-A-reductase inhibitors without CK-elevation? Atherosclerosis 149:225PubMedCrossRefGoogle Scholar
  95. Sinzinger H, Wolfram R, Peskar BA (2002) Muscular side effects of statins. J Cardiovasc Pharmacol 40:163–171PubMedCrossRefGoogle Scholar
  96. Sironi L et al (2006) Activation of NF-kB and ERK1/2 after permanent focal ischemia is abolished by simvastatin treatment. Neurobiol Dis 22:445–451PubMedCrossRefGoogle Scholar
  97. Sirtori CR (2014) The pharmacology of statins. Pharmacol Res 88:3–11PubMedCrossRefGoogle Scholar
  98. Sirvent P, Mercier J, Lacampagne A (2008) New insights into mechanisms of statin-associated myotoxicity. Curr Opin Pharmacol 8:333–338PubMedCrossRefGoogle Scholar
  99. Skilving I, Acimovic J, Rane A, Ovesjö ML, Björkhem-Bergman L (2015) Statin-induced myopathy and ubiquinone levels in serum-results from a prospective, observational study. Basic Clin Pharmacol Toxicol 117:133–136PubMedCrossRefGoogle Scholar
  100. Skripova D, Daniel P, Katarina K, Rafael R (2010) Is there is need for ubiquinone (CoQ10) supplementation in statin-associated myopathy? Open Nutraceuticals J 3:242–247CrossRefGoogle Scholar
  101. Smith LL (1981) Cholesterol autoxidation. Springer Science & Business Media, BerlinCrossRefGoogle Scholar
  102. Smith LL (1987) Cholesterol autoxidation 1981–1986. Chem Phys Lipid 44:87–125CrossRefGoogle Scholar
  103. Smith LL (1991) Another cholesterol hypothesis: cholesterol as antioxidant. Free Radic Biol Med 11:47–61PubMedCrossRefGoogle Scholar
  104. Solomon KR, Freeman MR (2008) Do the cholesterol-lowering properties of statins affect cancer risk? Trends Endocrinol Metab 19:113–121PubMedCrossRefGoogle Scholar
  105. Stancu C, Sima A (2001) Statins: mechanism of action and effects. J Cell Mol Med 5:378–387PubMedCrossRefGoogle Scholar
  106. St-Pierre J, Buckingham JA, Roebuck SJ, Brand MD (2002) Topology of superoxide production from different sites in the mitochondrial electron transport chain. J Biol Chem 277:44784–44790PubMedCrossRefGoogle Scholar
  107. Sugiyama S, Kitazawa M, Ozawa T, Suzuki K, Izawa Y (1980) Anti-oxidative effect of coenzyme Q 10. Cell Mol Life Sci 36:1002–1003CrossRefGoogle Scholar
  108. Taylor ML, Wells BJ, Smolak MJ (2008) Statins and cancer: a meta-analysis of case–control studies. Eur J Cancer Prev 17:259–268PubMedCrossRefGoogle Scholar
  109. Thompson PD, Clarkson P, Karas RH (2003) Statin-associated myopathy. JAMA 289:1681–1690PubMedCrossRefGoogle Scholar
  110. Tomaszewski M, Stępień KM, Tomaszewska J, Czuczwar SJ (2011) Statin-induced myopathies. Pharmacol Rep 63:859–866PubMedCrossRefGoogle Scholar
  111. Usui H et al (2003) HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats. Nephrol Dial Transplant 18:265–272PubMedCrossRefGoogle Scholar
  112. Vaklavas C, Chatzizisis YS, Ziakas A, Zamboulis C, Giannoglou GD (2009) Molecular basis of statin-associated myopathy. Atherosclerosis 202:18–28PubMedCrossRefGoogle Scholar
  113. Vaziri ND, Dicus M, Ho ND, Boroujerdi-Rad L, Sindhu RK (2003) Oxidative stress and dysregulation of superoxide dismutase and NADPH oxidase in renal insufficiency. Kidney Int 63:179–185PubMedCrossRefGoogle Scholar
  114. Wahane V, Kumar V (2010) Atorvastatin ameliorates inflammatory hyperalgesia in rat model of monoarticular arthritis. Pharmacol Res 61:329–333PubMedCrossRefGoogle Scholar
  115. Wassmann S et al (2002) Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 22:300–305PubMedCrossRefGoogle Scholar
  116. Willis RA, Folkers K, Tucker JL, Ye C-Q, Xia L-J, Tamagawa H (1990) Lovastatin decreases coenzyme Q levels in rats. Proc Natl Acad Sci 87:8928–8930PubMedPubMedCentralCrossRefGoogle Scholar
  117. Wood WG, Mΰller WE, Eckert GP (2014) Statins and neuroprotection: basic pharmacology needed. Mol Neurobiol 50:214–220PubMedCrossRefGoogle Scholar
  118. Yoshida M, Shiojima I, Ikeda H, Komuro I (2009) Chronic doxorubicin cardiotoxicity is mediated by oxidative DNA damage-ATM-p53-apoptosis pathway and attenuated by pitavastatin through the inhibition of Rac1 activity. J Mol Cell Cardiol 47:698–705PubMedCrossRefGoogle Scholar
  119. Yu H, Pardoll D, Jove R (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9:798–809PubMedPubMedCentralCrossRefGoogle Scholar
  120. Zafarullah M, Li W, Sylvester J, Ahmad M (2003) Molecular mechanisms of N-acetylcysteine actions. Cell Mol Life Sci CMLS 60:6–20PubMedCrossRefGoogle Scholar
  121. 三浦進司, 渡辺順一, 佐藤満昭, 富田多嘉子, 大澤俊彦, 原征彦, 富田勲 (1995) Effects of various natural antioxidants on the Cu2+ -mediated oxidative modification of low density lipoprotein. Biol Pharm Bull 18:1–4Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Student Research CommitteeTabriz University of Medical SciencesTabrizIran
  2. 2.Biotechnology Research CenterTabriz University of Medical SciencesTabrizIran
  3. 3.Department of Biochemistry and Clinical LaboratoriesTehran University of Medical SciencesTehranIran
  4. 4.Nutritional Research CenterTabriz University of Medical SciencesTabrizIran

Personalised recommendations